Published in Transl Lung Cancer Res on December 01, 2016
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. Oncotarget (2017) 0.75
Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases. FEBS Lett (2007) 2.43
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract (2014) 1.64
Selection of the optimal manual method of cell free fetal DNA isolation from maternal plasma. Clin Chem Lab Med (2013) 1.47
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer (2009) 1.40
Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer (2001) 1.13
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Characterization of circulating DNA in healthy human plasma. Clin Chim Acta (2007) 1.12
Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res (2012) 1.01
Circulating nucleosomes in serum. Ann N Y Acad Sci (2001) 0.99
Apoptosis in serum of patients with solid tumours. Anticancer Res (1999) 0.94
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer (2012) 0.91
Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem (2009) 0.86
Akonni TruTip(®) and Qiagen(®) methods for extraction of fetal circulating DNA--evaluation by real-time and digital PCR. PLoS One (2013) 0.85